Patents by Inventor Vojo Deretic

Vojo Deretic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12285470
    Abstract: Tie present invention relates to compositions and methods of influencing autophagy by modulating TRIM (tripartite motif containing) proteins, especially TRIM 8, TRIM: 10, TRIM 16, TRIM 19 and/or TRIM 51 (preferably TRIM 16} and galectins, especially galectins 3 m order to influence autophagy and treat a number of disease states and/or conditions which are mediated and/or influenced by autophagy, including inflammatory disease states and/or conditions, including a microbial infection such as a Mycobacterium infection, among numerous others, an inflammatory disorder, a lysosomal, storage disorder, an immune disorder, a neurodegenerative disorder and a cancer.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: April 29, 2025
    Assignee: UNM RAINFOREST INNOVATIONS
    Inventor: Vojo Deretic
  • Publication number: 20250043285
    Abstract: The present invention relates to discovery that modulators of ATG8 and/or ATG9A act in sequence to orchestrate the sealing of autophagosomal membranes. The present invention is directed to use of these agents and this mechanism in the treatment of various disease states and/or conditions, especially cancer.
    Type: Application
    Filed: July 2, 2024
    Publication date: February 6, 2025
    Inventors: Vojo Deretic, Graham Timmins, Rujeena Javed
  • Publication number: 20240261378
    Abstract: Tie present invention relates to compositions and methods of influencing autophagy by modulating TRIM (tripartite motif containing) proteins, especially TRIM 8, TRIM: 10, TRIM 16, TRIM 19 and/or TRIM 51 (preferably TRIM 16} and galectins, especially galectins 3 m order to influence autophagy and treat a number of disease states and/or conditions which are mediated and/or influenced by autophagy, including inflammatory disease states and/or conditions, including a microbial infection such as a Mycobacterium infection, among numerous others, an inflammatory disorder, a lysosomal, storage disorder, an immune disorder, a neurodegenerative disorder and a cancer.
    Type: Application
    Filed: July 31, 2017
    Publication date: August 8, 2024
    Inventor: Vojo Deretic
  • Publication number: 20190060289
    Abstract: The invention provides methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention provides a method of determining whether a subject suffers from, or is at risk of developing, and autophagy mediated disease state and/or condition by evaluating LC3 levels.
    Type: Application
    Filed: August 13, 2018
    Publication date: February 28, 2019
    Inventors: Vojo Deretic, Eliseo Castillo, Steven Bradfute, Larry A Sklar
  • Publication number: 20170112813
    Abstract: The invention provides methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention provides a method of determining whether a subject suffers from, or is at risk of developing, and autophagy mediated disease state and/or condition by evaluating LC3 levels.
    Type: Application
    Filed: October 6, 2016
    Publication date: April 27, 2017
    Inventors: Vojo Deretic, Eliseo Castillo, Steven Bradfute, Larry A. Sklar
  • Patent number: 9572820
    Abstract: The invention provides methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention provides a method of determining whether a subject suffers from, or is at risk of developing, and autophagy mediated disease state and/or condition by evaluating LC3 levels.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: February 21, 2017
    Assignee: STC.UNM
    Inventors: Vojo Deretic, Eliseo Castillo, Steven Bradfute, Larry A. Sklar
  • Publication number: 20140135296
    Abstract: The invention provides methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention provides a method of determining whether a subject suffers from, or is at risk of developing, and autophagy mediated disease state and/or condition by evaluating LC3 levels.
    Type: Application
    Filed: May 10, 2012
    Publication date: May 15, 2014
    Inventors: Vojo Deretic, Eliseo Castillo, Steven Bradfute, Larry A. Sklar
  • Patent number: 6426187
    Abstract: Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Chronic respiratory infections with mucoid Pseudomonas aeruginosa are the leading cause of high mortality and morbidity in cystic fibrosis. The initially colonizing strains are nonmucoid but in the cystic fibrosis lung they invariably convert into the mucoid form causing further disease deterioration and poor prognosis. Mucoidy is a critical P. aeruginosa virulence factor in cystic fibrosis that has been associated with biofilm develoment and resistance to phagocytosis. The molecular basis of this conversion to mucoidy is also disclosed. The present invention provides for detecting the switch from nonmucoid to mucoid state as caused by either frameshift deletions and duplications or nonsense changes in the second gene of the cluster, mucA. Inactivation of mucA results in constitutive expression of genes, such as algD, dependent on algU for transcription.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: July 30, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: Vojo Deretic, Daniel W. Martin
  • Patent number: 6083691
    Abstract: Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Chronic respiratory infections with mucoid Pseudomonas aeruginosa are the leading cause of high mortality and morbidity in cystic fibrosis. The initially colonizing strains are nonmucoid but in the cystic fibrosis lung they invariably convert into the mucoid form causing further disease deterioration and poor prognosis. Mucoidy is a critical P. aeruginosa virulence factor in cystic fibrosis that has been associated with biofilm development and resistance to phagocytosis. The molecular basis of this conversion to mucoidy is also disclosed. The present invention provides for detecting the switch from nonmucoid to mucoid state as caused by either frameshift deletions and duplications or nonsense changes in the second gene of the cluster, mucA. Inactivation of mucA results in constitutive expression of genes, such as algD, dependent on algU for transcription.
    Type: Grant
    Filed: November 24, 1995
    Date of Patent: July 4, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Vojo Deretic, Daniel W. Martin
  • Patent number: 5591838
    Abstract: Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Chronic respiratory infections with mucoid Pseudomonas aeruginosa are the leading cause of high mortality and morbidity in cystic fibrosis. The initially colonizing strains are nonmucoid but in the cystic fibrosis lung they invariably convert into the mucoid form causing further disease deterioration and poor prognosis. The molecular basis of this conversion to mucoidy is also disclosed. The algU gene encodes a protein homologous to an alternative sigma factor regulating sporulation and other developmental processes in Bacillus, and along with the negative regulators mucA and mucB comprises the gene cluster controlling conversion to mucoidy. The switch from nonmucoid to mucoid state is caused by frameshift deletions and duplications in the second gene of the cluster, mucA. Inactivation of mucA results in constitutive expression of genes, such as algD, dependent on algU for transcription.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: January 7, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Vojo Deretic, Daniel W. Martin
  • Patent number: 5573910
    Abstract: Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Mucoidy is a critical P. aeruginosa virulence factor in cystic fibrosis that has been associated with biofilm develoment and resistance to phagocytosis. The present invention provides for detecting the switch from nonmucoid to mucoid state as caused by the interaction of the algU gene product, algU, with RNA polymerase. Inactivation of algU results in a loss of expression of genes, such as algD, dependent on algU for transcription. Also disclosed is a novel alginate biosynthesis heterologous expression system for use in screening candidate substances that inhibit conversion to mucoidy by inhibiting the interaction of algU with the RNA polymerase holoenzyme.
    Type: Grant
    Filed: June 15, 1994
    Date of Patent: November 12, 1996
    Assignee: Board of Regents, The University of Texas System
    Inventors: Vojo Deretic, Daniel W. Martin